Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epcoritamab With GDP Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma
NCT05852717Phase 2Recruiting
- Start
- Oct 2023
- Primary completion
- Nov 2027
- Modality
- Antibody Conjugates, Bispecific Antibodies, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of epcoritamab in diffuse large B-cell lymphoma (DLBCL) (2 arms). Primary endpoint: Complete Response at 4 years. Started Oct 2023; status: recruiting.
02
Drugs
epcoritamab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT05852717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05852717.